The protection of intellectual property (IP) inside the burgeoning market for psychedelics and psychedelic-assisted therapy is prompting important debate and discussion. How are companies patenting medicines that have been used for millennia? Does copyright of guidelines for psychedelic-assisted therapy prohibit people from using those guidelines without a license? What role can trademarks, appellations of origin, and geographical indicators play in creating certifications for guides and products? Can IP be used to improve access to knowledge, access to medicine, and reciprocity with historically marginalized communities?
